Amphastar [AMPH] vs Zoetis [ZTS] Detailed Stock Comparison

Amphastar Pharmaceuticals Inc.

NASDAQ
Loading...

Zoetis Inc.

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Amphastar Pharmaceuticals Inc. wins in 8 metrics, Zoetis Inc. wins in 12 metrics, with 0 ties. Zoetis Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Amphastar Pharmaceuticals Inc. Zoetis Inc. Better
P/E Ratio (TTM) 10.34 19.58 Amphastar Pharmaceuticals Inc.
Price-to-Book Ratio 1.24 15.04 Amphastar Pharmaceuticals Inc.
Debt-to-Equity Ratio 83.16 279.59 Amphastar Pharmaceuticals Inc.
PEG Ratio -0.31 2.81 Zoetis Inc.
EV/EBITDA 6.11 13.96 Amphastar Pharmaceuticals Inc.
Profit Margin (TTM) 13.63% 28.24% Zoetis Inc.
Operating Margin (TTM) 19.45% 34.69% Zoetis Inc.
EBITDA Margin (TTM) 19.45% 34.69% Zoetis Inc.
Return on Equity 12.90% 65.99% Zoetis Inc.
Return on Assets (TTM) 6.37% 15.26% Zoetis Inc.
Free Cash Flow (TTM) $118.98M $2.28B Zoetis Inc.
Dividend Yield N/A 1.21% N/A
1-Year Return -26.68% -53.93% Amphastar Pharmaceuticals Inc.
Price-to-Sales Ratio (TTM) 1.32 5.26 Amphastar Pharmaceuticals Inc.
Enterprise Value $1.34B $56.75B Zoetis Inc.
EV/Revenue Ratio 1.87 6.00 Amphastar Pharmaceuticals Inc.
Gross Profit Margin (TTM) 46.79% 70.17% Zoetis Inc.
Revenue per Share (TTM) $15 $21 Zoetis Inc.
Earnings per Share (Diluted) $2.07 $6.02 Zoetis Inc.
Beta (Stock Volatility) 0.91 0.97 Amphastar Pharmaceuticals Inc.
Short % of Float 16.32% 4.06% Zoetis Inc.

Amphastar Pharmaceuticals Inc. vs Zoetis Inc. Stock Performance Analysis

Loading Price Chart...

AMPH
ZTS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Amphastar Pharmaceuticals Inc.-1.79%-5.13%-20.32%-8.62%-34.30%-31.52%
Zoetis Inc.1.51%-4.46%-31.75%-39.76%-38.95%-38.30%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Amphastar Pharmaceuticals Inc.-26.68%-59.64%0.32%19.46%79.52%79.52%
Zoetis Inc.-53.93%-54.80%-55.66%62.09%150.53%150.53%

Performance & Financial Health Analysis: Amphastar Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMPHZTS
Market Information
Market Cap i$953.49M$49.75B
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i454,6912,727,710
90 Day Avg. Volume i496,5743,835,940
Last Close$18.12$167.10
52 Week Range$16.65 - $31.26$139.70 - $200.33
% from 52W High-42.03%-16.59%
All-Time High$67.66 (Aug 07, 2023)$249.27 (Dec 27, 2021)
% from All-Time High-73.22%-32.96%
Growth Metrics
Quarterly Revenue Growth-0.02%0.03%
Quarterly Earnings Growth-0.36%0.04%
Financial Health
Profit Margin (TTM) i0.14%0.28%
Operating Margin (TTM) i0.19%0.35%
Return on Equity (TTM) i0.13%0.66%
Debt to Equity (MRQ) i83.16279.59
Cash & Liquidity
Book Value per Share (MRQ)$17.28$7.84
Cash per Share (MRQ)$6.23$5.48
Operating Cash Flow (TTM) i$156.12M$2.90B
Levered Free Cash Flow (TTM) i$81.37M$1.79B
Dividends
Last 12-Month Dividend Yield iN/A1.21%
Last 12-Month Dividend iN/A$2.03

Valuation & Enterprise Metrics Analysis: Amphastar Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMPH (Apr 26, 2026)ZTS (Apr 13, 2026)
Price Ratios
P/E Ratio (TTM) i10.3419.58
Forward P/E i6.1815.61
PEG Ratio i-0.312.81
Price to Sales (TTM) i1.325.26
Price to Book (MRQ) i1.2415.04
Market Capitalization
Market Capitalization i$953.49M$49.75B
Enterprise Value i$1.34B$56.75B
Enterprise Value Metrics
Enterprise to Revenue i1.876.00
Enterprise to EBITDA i6.1113.96
Risk & Other Metrics
Beta i0.910.97
Book Value per Share (MRQ) i$17.28$7.84

Financial Statements Comparison: Amphastar Pharmaceuticals Inc. vs Zoetis Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricAMPH (2025)ZTS (2025)
Revenue/Sales i719.89M9.47B
Cost of Goods Sold i363.83M2.67B
COGS % of Revenue i50.5%28.2%
Gross Profit i356.06M6.80B
Gross Margin i49.5%71.8%
Research & Development i85.84M698.00M
Operating Income (EBIT) i140.40M3.60B
Operating Margin i19.5%38.0%
EBITDA i212.31M4.17B
EBITDA Margin i29.5%44.1%
Pre-Tax Income i123.62M3.36B
Pre-Tax Income % of Revenue i17.2%35.5%
Income Tax i25.53M687.00M
Income Tax % of Revenue i3.5%7.3%
Net Income (Profit) i98.09M2.67B
Profit Margin i13.6%28.2%

Balance Sheet & Liquidity Metrics

MetricAMPH (2025)ZTS (2025)
Cash & Equivalents i170.18M2.31B
Total Current Assets i636.02M6.77B
Total Current Assets % of Revenue i88.3%71.5%
Total Current Liabilities i158.16M2.24B
Total Current Liabilities % of Revenue i22.0%23.6%
Long-Term Debt i646.43M9.24B
Long-Term Debt % of Revenue i89.8%97.6%
Total Shareholders Equity i788.81M3.33B
Retained Earnings i666.88M13.74B
Retained Earnings % of Revenue i92.6%145.2%
Property, Plant & Equipment i43.15M288.00M

Cash Flow Statement Comparison

MetricAMPH (2025)ZTS (2025)
Operating Cash Flow i157.11M2.78B
Operating Cash Flow % of Revenue i21.8%29.3%
Capital Expenditures i-34.88MN/A
Free Cash Flow i118.98M2.28B
FCF Margin i16.5%24.1%
Debt Repayment i-223,000-1.35B
Common Stock Repurchase i-75.59M-3.24B

Short Interest & Institutional Ownership Analysis

MetricAMPHZTS
Shares Short i3.53M15.12M
Short Ratio i5.633.60
Short % of Float i16.32%4.06%
Shares Outstanding i45.65M424.93M
Float Shares i33.90M421.29M
% Held by Insiders i29.34%0.15%
% Held by Institutions i78.52%101.50%
% Held by Public i-7.86%-1.65%

Dividend Analysis & Yield Comparison: Amphastar Pharmaceuticals Inc. vs Zoetis Inc.

MetricAMPHZTS
Last 12-Month Dividend iN/A$2.03
Last 12-Month Dividend Yield iN/A1.21%
3-Year Avg Annual Dividend iN/A$1.80
3-Year Avg Dividend Yield iN/A0.29%
3-Year Total Dividends iN/A$5.39
Ex-Dividend DateN/AJan 20, 2026